Category: Takeda Pharmaceutical

Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft

BioPharma, Daily, deals, Immusoft, Japan, metabolic disorders, neurological disease, Pharma, Seattle, SYN, Takeda Pharmaceutical, Top Story / October 13, 2021 October 13, 2021

Takeda Pharmaceutical is partnering with startup Immusoft in a research alliance aiming to develop B cell therapies that cross the blood-brain barrier to treat rare neurometabolic disorders. Depending on the progress of the research, Takeda could pay its new partner more than $900 million.

Takeda broadens gene therapy scope, turns to Poseida for non-viral approach

BioPharma, biopharma nl, Daily, deals, gene therapy, hemophilia A, Japan, Pharma, Poseida Therapeutics, San Diego, SYN, Takeda Pharmaceutical, Top Story / October 12, 2021 October 12, 2021

The progress of gene therapies continues to be stymied by safety risks associated with the viruses used to deliver them. Takeda Pharmaceutical is partnering with Poseida Therapeutics in a bet that the biotech’s non-viral technologies could offer a safer alternative.

Takeda therapy gets speedy FDA nod for lung cancers with rare genetic signature

BioPharma, biopharma nl, cancer, Clinical Trials, Daily, Exkivity, FDA, Japan, Legal, Non-Small Cell Lung Cancer, Pharma, SYN, Takeda Pharmaceutical, Tokyo, Top Story / September 16, 2021 September 16, 2021

Takeda Pharmaceutical drug mobocertinib was approved by the FDA to treat non-small cell lung cancer in patients whose tumors carry a rare genetic signature. With the approval, Takeda can offer an oral alternative to a recently approved Johnson & Johnson drug that targets the same mutation but is given as an infusion.

Novartis “one transplant for life” drug flunks test in kidney transplant patients

BioPharma, biopharma nl, Clinical Trial, Daily, Forte Biosciences, iscalimab, News, Novartis, organ transplant, Pharma, SYN, Takeda Pharmaceutical, Top Story / September 3, 2021 September 3, 2021

A Novartis drug intended to prevent organ rejection has failed to beat out the standard of care therapy in a Phase 2 study in kidney transplant patients. Other clinical trial failures announced ahead of the Labor Day weekend include a Forte Biosciences atopic dermatitis drug, as well a cancer therapy from Takeda Pharmaceutical.

Takeda to buy out Maverick in $525M bet on bringing T cells to solid tumors

Acquisitions, BioPharma, biopharma nl, Brisbane, California, cancer immunotherapy, Daily, Maverick Therapeutics, Pharma, SYN, Takeda Pharmaceutical, Top Story / March 9, 2021 March 9, 2021

Takeda Pharmaceutical and Maverick Therapeutics have been R&D partners since 2017. In buying out its partner, Takeda acquires technology and drug candidates that could offer advantages compared to CAR-T therapies, including the potential to treat solid tumors.

Takeda to pay Ovid $196M for full rights to Phase 3-ready epilepsy drug

BioPharma, biopharma nl, Daily, epilepsy, New York, ovid therapeutics, Pharma, Rare diseases, SYN, Takeda Pharmaceutical, Tokyo, Top Story / March 3, 2021 March 3, 2021

Takeda Pharmaceutical gains full rights to a small molecule that has shown promise treating seizures in several rare forms of epilepsy. Meanwhile, Ovid Therapeutics gains cash to support its pipeline of neurological disease drug candidates.

Ovid drug reduces seizure frequency in two rare forms of epilepsy, according to early Phase II data

BioPharma, biopharma nl, CDKL5 deficiency disorder, Daily, Dup15q syndrome, epilepsy, New York, ovid therapeutics, SYN, Takeda Pharmaceutical, Top Story / October 1, 2020 October 1, 2020

The data from a Phase II pilot and an extension study of soticlestat, also known as OV935 or TAK-935, showed short- and long-term reductions of seizure frequency in patients with CDKL5 deficiency disorder and Dup15q syndrome.

Platform study designed to rapidly screen potential Covid-19 drugs enrolls first patients

AbbVie, Amgen, apremilast, BioPharma, biopharma nl, California, cenicriviroc, coronavirus, Covid R&D Alliance, COVID-19, Daily, Firazyr, Food and Drug Administration, I-SPY COVID-19, icatibant, Otezla, Policy, QuantumLeap Healthcare Collaborative, SARS-CoV-2, SYN, Takeda Pharmaceutical, Thousand Oaks, Top Story / August 3, 2020 August 3, 2020

Three of the companies making drugs used in the Phase II I-SPY COVID-19 study – Amgen, AbbVie and Takeda – announced the patient enrollments Monday. The study, which will enroll up to 1,500 critically ill patients, could test around 10 drugs.